Edition:
United States

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

86.70USD
10:13am EST
Change (% chg)

$3.19 (+3.82%)
Prev Close
$83.51
Open
$84.67
Day's High
$87.52
Day's Low
$84.67
Volume
123,785
Avg. Vol
469,842
52-wk High
$107.02
52-wk Low
$62.22

BMRN.OQ

Chart for BMRN.OQ

About

BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company's product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha),... (more)

Overall

Beta: 1.54
Market Cap(Mil.): $14,362.67
Shares Outstanding(Mil.): 171.99
Dividend: --
Yield (%): --

Financials

  BMRN.OQ Industry Sector
P/E (TTM): -- 29.74 30.35
EPS (TTM): -2.96 -- --
ROI: -14.42 15.90 15.27
ROE: -19.56 17.00 16.60

BRIEF-BioMarin announces Q3 GAAP loss per share of $0.26

* Q3 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S

Oct 27 2016

BRIEF-Biomarin Pharmaceutical provided update on mod-stage study of vosoritide

* Biomarin Pharmaceutical - Provided update on phase 2 study of vosoritide, analog of C-type Natriuretic Peptide (CNP), in children with achondroplasia

Oct 19 2016

BRIEF-UK regulatory agency approves continued enrollment in Biomarin phase 1/2 study

* UK regulatory agency approves continued enrollment in Biomarin phase 1/2 study of BMN 270 in Hemophilia a

Oct 13 2016

BRIEF-BioMarin reviews status of Exon 51 composition of matter

* To seek review of patent trial and appeal board ruling, for composition of matter claims related to exon 51 skipping antisense oligonucleotides

Sep 21 2016

BRIEF-BioMarin announces update to Brineura program

* BioMarin announces update to Brineura (cerliponase alfa) program for treatment of CLN2 disease, a form of batten disease

Sep 06 2016

BRIEF-Temasek Holdings raises share stake in Alibaba Group, takes share stake in B/E Aerospace

* Temasek Holdings raises share stake in Alibaba Group Holding Ltd By 13.7 pct to 54.08 mln shares - SEC filing

Aug 15 2016

BRIEF-Biomarin Pharmaceutical announces pricing of public offering of common stock

* Biomarin announces pricing of public offering of common stock

Aug 09 2016

BRIEF-Biomarin Pharmaceutical files for potential mixed shelf offering

* Files for potential mixed shelf offering; size not disclosed - SEC filing Source text: http://bit.ly/2b45rwC Further company coverage:

Aug 08 2016

BRIEF-Biomarin says offering of 7.5 mln shares of stock

* Says offering of 7.5 million shares of its common stock in an underwritten public offering Source text for Eikon: Further company coverage:

Aug 08 2016

BRIEF-Biomarin Pharmaceutical Q2 GAAP loss per share $2.61

* Q2 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S

Aug 04 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $111.66 +0.67
Pfizer Inc. (PFE.N) $31.67 +0.73
Novartis AG (NOVN.S) CHF70.85 +2.35
Merck & Co., Inc. (MRK.N) $60.90 +0.78
Roche Holding Ltd. (ROG.S) CHF227.20 +6.80
Roche Holding Ltd. (RO.S) CHF231.10 +5.00
Abbott Laboratories (ABT.N) $38.96 +0.28
Bayer AG (BAYGn.DE) €94.23 +1.06
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €76.76 +1.68

Earnings vs. Estimates